A Phase 2, Open Label, Pharmacokinetic (PK) Study of TLC599 in Subjects With Osteoarthritis of the Knee

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

102 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-21

Study Completion Date

2023-11-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a multi-center, Phase 2, open-label, 1-period, parallel study with 9 cohorts of subjects with osteoarthritis (OA) of the knee enrolled to receive single-dose of TLC599 or Dexamethasone sodium phosphate (DSP) via IA injection and 1 cohort of healthy subjects to receive single-dose of DSP via intravenous (IV) injection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Extended and Controlled Release Liposomal Formulated Dexamethasone for Chronic Knee OA Pain

NCT04123561

Osteoarthritis of the Knee

COMPLETED PHASE3

Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for TLC599 in OA Patients

NCT03005873

Osteoarthritis of the Knee

COMPLETED PHASE2

Single-Dose Administration Trial of TLC599 in Osteoarthritis of the Knee

NCT02803307

Osteoarthritis of the Knee

COMPLETED PHASE1/PHASE2

A Study to Evaluate the Safety and Efficacy of 2ccPA in Patients With Symptomatic Knee Osteoarthritis

NCT05807529

Osteoarthritis, Knee

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

2ccPA Study in Patients With Symptomatic Knee Osteoarthritis

NCT04229394

Osteoarthritis (OA) of the Knee

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This Phase 2, open-label, 1 period, parallel study will enroll

1. approximately 90 subjects to receive a single dose of TLC599 or DSP via intra-articular (IA) injection, followed by a PK evaluation period up to 24 weeks and an additional follow-up period of 1 to 5 weeks. Additional subjects may be recruited as needed to achieve at least 10 subjects completing the 1-week blood collection period for each treatment.
2. approximately 12 healthy subjects to receive a single dose of DSP via IV injection, followed by a PK evaluation period up to 1 week and an additional follow-up period of 1 week. Additional subjects may be recruited as needed to achieve at least 12 subjects completing the 48-hour blood collection period for IV DSP.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis of the Knee

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TLC599 12 mg

12 mg TLC590 (proprietary lipid formulation that consists of 12 mg DSP \[active ingredient\] with 100 μmol phospholipid) via IA injection in patients with OA of the knee. This 12 mg TLC599 treatment arm consists of six (6) cohorts (G1 to G6), each with different follow-up periods or visit schedules. However, the results will be pooled into a single treatment arm to allow for meaningful analysis across the various synovial fluid (SF) time points, as each subject only has one opportunity to collect an SF sample.

Group Type EXPERIMENTAL

TLC599

Intervention Type DRUG

TLC599 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP (active ingredient).

TLC599 6 mg

6 mg TLC590 (proprietary lipid formulation that consists of 6 mg DSP \[active ingredient\] with 50 μmol phospholipid) via IA injection in patients with OA of the knee. This 6 mg TLC599 treatment arm consists of two (2) cohorts (G7 and G8), each with different follow-up periods or visit schedules. However, the results will be pooled into a single treatment arm to allow for meaningful analysis across the various synovial fluid (SF) time points, as each subject only has one opportunity to collect an SF sample.

Group Type EXPERIMENTAL

TLC599

Intervention Type DRUG

TLC599 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP (active ingredient).

DSP 4 mg

Dexamethasone Sodium Phosphate (DSP) at a concentration of 4 mg/mL, 1 mL for a total of 4 mg DSP via IA injection in patients with OA of the knee (G9).

Group Type ACTIVE_COMPARATOR

DSP

Intervention Type DRUG

Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.

DSP 10 mg

Dexamethasone Sodium Phosphate (DSP) at a concentration of 4 mg/mL, 2.5 mL for the total of 10 mg DSP via IV injection in healthy subjects (G10).

Group Type ACTIVE_COMPARATOR

DSP

Intervention Type DRUG

Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TLC599

TLC599 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP (active ingredient).

Intervention Type DRUG

DSP

Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

TLC599 Injection Dexamethasone Sodium Phosphate

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 45 or older, non or moderate smokers, body mass index (BMI) ≤ 40.0 kg/m2.
* Knee OA symptoms with confirmed mild to moderate OA.
* Study knee OA severity grade 1-3 (Kellgren-Lawrence).
* Agree to use contraception

* Age 18-45, non-smokers, BMI 18.5-25 kg/m2, body weight ≥ 50.0 kg (males) or ≥ 45.0 kg (females).
* Healthy with no CS illness/surgery within 4 weeks or CS medical history.
* Agree to use contraception
* No new tattoos/body piercings at the injection site until the study ends.

Exclusion Criteria

* Clinically significant (CS) abnormalities (physical, lab, hepatitis B/C, HIV, electrocardiogram \[ECG\], vital sign or unstable illness).
* Positive urine drug screen, tuberculosis (TB) test; significant alcohol/drug abuse
* Allergic reactions to TLC599, its components, related drugs or cosyntropin.
* History of autoimmune disease, immunodeficiency diseases, treated malignancy, CS opportunistic infection, tuberculosis, infective arthritis or concurrent knee infection
* Intra-articular bleeding in study knee.
* Skin issues at injection site or hindrance to knee joint penetration.
* Blood coagulation disorders.
* Stroke or myocardial infarction
* Poorly controlled hypertension or vital sign abnormalities.
* Interfering conditions with dosing, visits, or compliance or refusal of synovial fluid collection.
* Medication: Strong/moderate Cytochrome P450 (CYP) 3A/3A4 inhibitors/inducers, prescription meds, over-the-counter (OTC)/natural health products, meds affecting platelet function, depot injection/implant, IA corticosteroid, hyaluronic acid, or other injection in study knee, impact on endogenous steroid levels, systemic corticosteroids, live attenuated vaccine, chemotherapeutic/immunosuppressant use for inflammatory diseases.
* Plasma donation or significant blood loss.
* Pregnancy, breastfeeding, or planning to be pregnant/breastfeed
* Serious local/systemic infection or symptomatic viral/bacterial infection
* Severe OA (grade 4) in non-study knee (Kellgren-Lawrence).
* Recent surgery, scheduled knee replacement or lower limb amputation.
* Known/adrenal insufficiency risk.
* Recent participation in other study research

Study Criteria for Healthy Subjects (Cohort G10)

* CS abnormal physical, ECG or vital sign findings.
* Known/adrenal insufficiency risk.
* Abnormal lab results (HBV, HCV, HIV, TB).
* Positive pregnancy test or lactating; positive urine drug screen or cotinine test.
* Significant alcohol/drug abuse or positive alcohol test.
* Significant drug allergies or allergic reactions to DSP, dexamethasone, cosyntropin, natural adrenocorticotropic hormone (ACTH), or other related drugs.
* History/presence of conditions including CS opportunistic infection, serious local/systemic infection, autoimmune, blood, heart, vascular, respiratory, lung, skin, liver, gallbladder, retinopathy, neuromuscular, cancer, kidney, diabetes, severe allergic reactions, or others that would preclude participation.
* Fever
* Active/latent tuberculosis or symptomatic viral/bacterial infection
* Medication: Depot injection/implant, vaccine, drug known to induce or inhibit CYP3A4 metabolism, prescription meds, OTC/natural health products.
* Consumption of specified fruits.
* Recent participation in other study research
* Plasma donation or significant blood loss.
* Reasons preventing study participation

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes